Publication of 2023 financial results and operating update
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Financial highlights include successful public rights offering and the subsequent 2024 buyback of all convertible bonds,…
Erste Wirksamkeitsdaten der klinischen Studie mit HDP-101 im Multiplen Myelom Prof. Dr. Andreas Pahl wird Sprecher des V…
Financial Highlights Direct MagnetOs sales rose by 155% to CHF 13.9 million in Q1 2024 from CHF 5.4 million in Q1 2023…
Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTCQB: INNPF) („Innocan“ oder das „Unternehmen“) freut sich bekannt z…
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…
bilacon – a Tentamus company – has opened a new laboratory in Zagreb, Croatia, in December 2023. The new facility is set…
Die 4SC AG (4SC, FSE Prime Standard: VSC), ein Biotech-Unternehmen, das das Leben von Patienten mit kutanem T-Zell-Lymph…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
Erleben Sie hautnah die vielschichtige Dynamik der Pharmaziebranche in Deutschland! Von der bewegenden Geschichte der Ap…
Removes the requirement to conduct paediatric clinical studies when the development of the medicine is not needed or is…